Daratumumab-based combinations with pomalidomide/dexamethasone (DPd), or bortezomib/dexamethasone (DVd), have shown activity in relapsed/refractory multiple myeloma (RRMM) patients. However, no direct comparisons of safety or efficacy of the two regimens have been published to date. We conducted a retrospective study to compare the safety and efficacy of DPd and DVd in daratumumab-naïve RRMM patients. We included 140 daratumumab-naïve patients who had received DPd or DVd for RRMM. Overall, the DPd group had a greater number of patients who had high-risk disease characteristics. Although response was deeper in the DPd group, the median progression-free survival (PFS) and overall survival (OS) were similar between the two groups. The DPd group exhibited a higher incidence of hematologic toxicities, whereas the DVd group had a higher incidence of peripheral neuropathy. The study results showed that while DPd may provide a deeper response, there was no significant difference in PFS or OS compared to DVd. For the high proportion of difficult-to-treat patients, duration of treatment may have contributed to these results, indicating that patient and disease characteristics should be considered when selecting salvage treatments.
基于达雷妥尤单抗联合泊马度胺/地塞米松（DPd）或硼替佐米/地塞米松（DVd）的治疗方案，在复发/难治性多发性骨髓瘤（RRMM）患者中已显示出疗效。然而，迄今为止尚未发表这两种方案安全性或有效性的直接比较研究。我们开展了一项回顾性研究，旨在比较DPd与DVd在未接受过达雷妥尤单抗治疗的RRMM患者中的安全性和有效性。研究共纳入140例未接受过达雷妥尤单抗治疗且接受DPd或DVd方案的RRMM患者。总体而言，DPd组中具有高危疾病特征的患者数量更多。尽管DPd组的治疗反应更为深入，但两组的中位无进展生存期（PFS）和总生存期（OS）相似。DPd组血液学毒性的发生率较高，而DVd组周围神经病变的发生率更高。研究结果表明，虽然DPd可能带来更深的治疗反应，但其PFS或OS与DVd相比并无显著差异。对于高比例难以治疗的患者，治疗持续时间可能影响了这些结果，这表明在选择挽救治疗方案时应考虑患者及疾病特征。
肿瘤(癌症)患者之家